Johnson & Johnson (NYSE:JNJ) on Tuesday reported a third-quarter 2025 adjusted earnings of $2.80 per share, up 15.7% year over year, beating the consensus of $2.75.
The pharmaceutical and medtech giant reported sales of $23.99 billion, up 6.8% year over year and beating the consensus of $23.74 billion. Operational growth was 5.4%, and adjusted operational growth was 4.4%.
